Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.4%

14 terminated/withdrawn out of 123 trials

Success Rate

81.1%

-5.4% vs industry average

Late-Stage Pipeline

13%

16 trials in Phase 3/4

Results Transparency

2%

1 of 60 completed trials have results

Key Signals

35 recruiting1 with results10 terminated4 withdrawn

Enrollment Performance

Analytics

N/A
57(54.8%)
Phase 2
22(21.2%)
Phase 1
9(8.7%)
Phase 3
9(8.7%)
Phase 4
7(6.7%)
104Total
N/A(57)
Phase 2(22)
Phase 1(9)
Phase 3(9)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (123)

Showing 20 of 123 trials
NCT05826509Phase 2Active Not Recruiting

SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer

Role: lead

NCT07195344Phase 4Recruiting

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Role: lead

NCT07558343Not ApplicableNot Yet Recruiting

Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2

Role: lead

NCT03966651Phase 1Completed

A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

Role: lead

NCT04513444Phase 2Recruiting

Interest of Medical Hypnosis in Anxious Patients Treated by Radiotherapy

Role: lead

NCT04740697Not ApplicableRecruiting

Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer

Role: lead

NCT05581121Phase 3Recruiting

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

Role: lead

NCT01574170Phase 4Completed

Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival

Role: lead

NCT00814021Phase 2Completed

Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain

Role: lead

NCT03953352Not ApplicableWithdrawn

Evaluation of the Automatic Deformable Recontouring on the Daily MVCT for Head and Neck Cancer Adaptive Radiotherapy

Role: lead

NCT02854215Not ApplicableCompleted

Cost Utility of Radical Surgery in Ovarian Cancer

Role: lead

NCT02857400Not ApplicableCompleted

Evaluation of an Organized Consultation "Return Home" of Patients With a Cancer (CREDO)

Role: lead

NCT00864318Phase 2Completed

Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis

Role: lead

NCT01507506Phase 3Terminated

Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma

Role: lead

NCT01642017Phase 1Terminated

Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria

Role: lead

NCT01118676Phase 1Completed

Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer

Role: lead

NCT03514381Phase 4Completed

Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma

Role: lead

NCT02311959Phase 3Completed

Therapeutic Nipple Sparing Mastectomy.

Role: lead

NCT03348891Not ApplicableCompleted

TNF in Melanoma Patients Treated With Immunotherapy

Role: lead

NCT01553903Phase 4Completed

Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not

Role: lead